Genomes and Genes

Species

David E Gerber

Summary

Affiliation: University of Texas Southwestern Medical Center
Country: USA

Publications

  1. Gerber D, Gupta P, Dellinger M, Toombs J, Peyton M, Duignan I, et al. Stromal platelet-derived growth factor receptor ? (PDGFR?) provides a therapeutic target independent of tumor cell PDGFR? expression in lung cancer xenografts. Mol Cancer Ther. 2012;11:2473-82 pubmed publisher
    ..We conclude that stromal PDGFR? inhibition represents a means for enhancing control of lung cancer growth in some cases, independent of tumor cell PDGFR? expression. ..
  2. Gerber D, Laccetti A, Xuan L, Halm E, Pruitt S. Impact of prior cancer on eligibility for lung cancer clinical trials. J Natl Cancer Inst. 2014;106: pubmed publisher
    ..This inclusion criterion is applied widely across studies, including more than two-thirds of trials with nonsurvival endpoints. More research is needed to understand the basis and ramifications of this exclusion policy. ..
  3. Gerber D, Spigel D, Giorgadze D, Shtivelband M, Ponomarova O, Shan J, et al. Docetaxel Combined With Bavituximab in Previously Treated, Advanced Nonsquamous Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2016;17:169-76 pubmed publisher
    ..This regimen is being evaluated in the ongoing, global, phase III SUNRISE trial. ..
  4. Laccetti A, Pruitt S, Xuan L, Halm E, Gerber D. Prior cancer does not adversely affect survival in locally advanced lung cancer: A national SEER-medicare analysis. Lung Cancer. 2016;98:106-113 pubmed publisher
    ..Patients with locally advanced lung cancer and a history of prior cancer should not be excluded from clinical trials, and should be offered aggressive, potentially curative therapies if otherwise appropriate. ..
  5. Dietrich M, Gerber D. Chemotherapy for Advanced Non-small Cell Lung Cancer. Cancer Treat Res. 2016;170:119-49 pubmed publisher
    ..Herein, we summarize the current concepts of chemotherapy, its applicability to the different histologies, and novel concepts of therapy. ..
  6. Le T, Mayer M, Sailors J, Gerber D, Truelson J. Upper lip metastasis of sarcomatoid carcinoma of the lung - an unusual site of disease: a case report. J Med Case Rep. 2017;11:18 pubmed publisher
    ..It highlights the importance of maintaining a high level of suspicion for metastatic disease in the presence of new cutaneous findings as they may be the first evidence of advanced disease. ..
  7. Gupta A, Saltarski J, White M, SCAGLIONI P, Gerber D. Therapeutic Targeting of Nuclear Export Inhibition in Lung Cancer. J Thorac Oncol. 2017;12:1446-1450 pubmed publisher
    ..A multicenter phase 1/2 clinical trial of selinexor in previously treated advanced KRAS-mutant NSCLC is under way. ..
  8. Gerber D, Hamann H, Santini N, Abbara S, Chiu H, McGuire M, et al. Patient navigation for lung cancer screening in an urban safety-net system: Protocol for a pragmatic randomized clinical trial. Contemp Clin Trials. 2017;60:78-85 pubmed publisher
    ..This study was registered with the NIH ClinicalTrials.gov database (NCT02758054) on April 26, 2016. ..
  9. Garcia S, Bisen A, Yan J, Xie X, Ramalingam S, Schiller J, et al. Thoracic Oncology Clinical Trial Eligibility Criteria and Requirements Continue to Increase in Number and Complexity. J Thorac Oncol. 2017;12:1489-1495 pubmed publisher
    ..Continued efforts to simplify protocol eligibility and procedures are warranted to promote trial adherence, enrollment, completion, and generalizability. ..
  10. Gerber D, Swanson P, Lopez Chavez A, Wong L, Dowlati A, Pennell N, et al. Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC. Lung Cancer. 2017;111:108-115 pubmed publisher
    ..Olaratumab studies in other patient populations, including soft tissue sarcoma (NCT02783599), pancreatic cancer (NCT03086369), and pediatric malignancies (NCT02677116) are underway. ..

Detail Information

Publications16

  1. Gerber D, Gupta P, Dellinger M, Toombs J, Peyton M, Duignan I, et al. Stromal platelet-derived growth factor receptor ? (PDGFR?) provides a therapeutic target independent of tumor cell PDGFR? expression in lung cancer xenografts. Mol Cancer Ther. 2012;11:2473-82 pubmed publisher
    ..We conclude that stromal PDGFR? inhibition represents a means for enhancing control of lung cancer growth in some cases, independent of tumor cell PDGFR? expression. ..
  2. Gerber D, Laccetti A, Xuan L, Halm E, Pruitt S. Impact of prior cancer on eligibility for lung cancer clinical trials. J Natl Cancer Inst. 2014;106: pubmed publisher
    ..This inclusion criterion is applied widely across studies, including more than two-thirds of trials with nonsurvival endpoints. More research is needed to understand the basis and ramifications of this exclusion policy. ..
  3. Gerber D, Spigel D, Giorgadze D, Shtivelband M, Ponomarova O, Shan J, et al. Docetaxel Combined With Bavituximab in Previously Treated, Advanced Nonsquamous Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2016;17:169-76 pubmed publisher
    ..This regimen is being evaluated in the ongoing, global, phase III SUNRISE trial. ..
  4. Laccetti A, Pruitt S, Xuan L, Halm E, Gerber D. Prior cancer does not adversely affect survival in locally advanced lung cancer: A national SEER-medicare analysis. Lung Cancer. 2016;98:106-113 pubmed publisher
    ..Patients with locally advanced lung cancer and a history of prior cancer should not be excluded from clinical trials, and should be offered aggressive, potentially curative therapies if otherwise appropriate. ..
  5. Dietrich M, Gerber D. Chemotherapy for Advanced Non-small Cell Lung Cancer. Cancer Treat Res. 2016;170:119-49 pubmed publisher
    ..Herein, we summarize the current concepts of chemotherapy, its applicability to the different histologies, and novel concepts of therapy. ..
  6. Le T, Mayer M, Sailors J, Gerber D, Truelson J. Upper lip metastasis of sarcomatoid carcinoma of the lung - an unusual site of disease: a case report. J Med Case Rep. 2017;11:18 pubmed publisher
    ..It highlights the importance of maintaining a high level of suspicion for metastatic disease in the presence of new cutaneous findings as they may be the first evidence of advanced disease. ..
  7. Gupta A, Saltarski J, White M, SCAGLIONI P, Gerber D. Therapeutic Targeting of Nuclear Export Inhibition in Lung Cancer. J Thorac Oncol. 2017;12:1446-1450 pubmed publisher
    ..A multicenter phase 1/2 clinical trial of selinexor in previously treated advanced KRAS-mutant NSCLC is under way. ..
  8. Gerber D, Hamann H, Santini N, Abbara S, Chiu H, McGuire M, et al. Patient navigation for lung cancer screening in an urban safety-net system: Protocol for a pragmatic randomized clinical trial. Contemp Clin Trials. 2017;60:78-85 pubmed publisher
    ..This study was registered with the NIH ClinicalTrials.gov database (NCT02758054) on April 26, 2016. ..
  9. Garcia S, Bisen A, Yan J, Xie X, Ramalingam S, Schiller J, et al. Thoracic Oncology Clinical Trial Eligibility Criteria and Requirements Continue to Increase in Number and Complexity. J Thorac Oncol. 2017;12:1489-1495 pubmed publisher
    ..Continued efforts to simplify protocol eligibility and procedures are warranted to promote trial adherence, enrollment, completion, and generalizability. ..
  10. Gerber D, Swanson P, Lopez Chavez A, Wong L, Dowlati A, Pennell N, et al. Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC. Lung Cancer. 2017;111:108-115 pubmed publisher
    ..Olaratumab studies in other patient populations, including soft tissue sarcoma (NCT02783599), pancreatic cancer (NCT03086369), and pediatric malignancies (NCT02677116) are underway. ..
  11. Yu H, Ahn M, Cho B, Gerber D, Natale R, Socinski M, et al. Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers. Lung Cancer. 2017;112:195-199 pubmed publisher
    ..Dacomitinib is a second-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Pre-clinical data suggest that intermittent pulsatile dosing of dacomitinib may result in inhibition of EGFR T790M...
  12. Gerber D, Socinski M, Neal J, Wakelee H, Shirai K, Sequist L, et al. Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer. Lung Cancer. 2018;117:44-49 pubmed publisher
    ..In previously treated patients with advanced KRAS mutant NSCLC, the combination of the MET inhibitor tivantinib and erlotinib is not superior to conventional single-agent chemotherapy. ..
  13. Gerber D, Urbanic J, Langer C, Hu C, Chang I, Lu B, et al. Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Non-Small-Cell Lung Cancer (RTOG 3505). Clin Lung Cancer. 2017;18:333-339 pubmed publisher
    ..This sample size will provideĀ ? 90% power to detect a hazard ratio of 0.7 for OS with 2-sided type I error of 0.04, and to detect a hazard ratio of 0.667 for PFS 2-sided type I error of 0.01. (NCT02768558). ..
  14. Le T, Sailors J, Oliver D, Mayer M, Hoskin S, Gerber D. Histologic transformation of EGFR mutant lung adenocarcinoma without exposure to EGFR inhibition. Lung Cancer. 2017;105:14-16 pubmed publisher
    ..Several mechanisms have been described. Here, we report the first case of histologic transformation of EGFR mutant lung adenocarcinoma without prior exposure to EGFR inhibition. ..
  15. Garcia S, Saltarski J, Yan J, Xie X, Gerber D. Time and Effort Required for Tissue Acquisition and Submission in Lung Cancer Clinical Trials. Clin Lung Cancer. 2017;18:626-630 pubmed publisher
    ..Improved systems to expedite these processes, as well as use of blood- or imaging-based biomarkers, may help address these issues. ..
  16. Khan S, Pruitt S, Xuan L, Makris U, Gerber D. How does autoimmune disease impact treatment and outcomes among patients with lung cancer? A national SEER-Medicare analysis. Lung Cancer. 2018;115:97-102 pubmed publisher
    ..Among patients with lung cancer, autoimmune disease does not influence treatment patterns and is not associated with mortality. ..